This document is a published patent application detailing novel compounds and compositions for cancer treatment, specifically targeting CBL-B inhibition. The application, filed by inventors Yingzhi BI, Kenneth G. CARSON, and Geraldine Cirillo HARRIMAN, outlines potential pharmaceutical uses and methods of making these compounds.

As this is a patent application, it does not impose immediate regulatory obligations on companies. However, it signals potential future patent protection for specific cancer treatments. Companies involved in oncology drug development should monitor this application and related patents to understand the intellectual property landscape and potential licensing or infringement considerations.